Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

2012 CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)

Part 2: Regional CRE Prevention

Appendix A: Previous and Current Clinical and Laboratory Standards Institute Interpretive Criteria for Carbapenems and Enterobacteriaceae

 

Agent Previous Breakpoints (M100-S19) MIC (μg/mL) Current Breakpoints (M100-S22) MIC (μg/mL)
Susceptible Intermediate Resistant Susceptible Intermediate Resistant
Doripenem - - - ≤1 2 ≥4
Ertapenem ≤2 4 ≥8 ≤0.5 1 ≥2
Imipenem ≤4 8 ≥16 ≤1 2 ≥4
Meropenem ≤4 8 ≥16 ≤1 2 ≥4

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty Second Informational Supplement (January 2012). CLSI document M100-S22. Wayne, Pennsylvania, 2012.

 

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO

 
CDC Carbapenem-resistant Enterobacteriaceae (CRE) Vital Signs report.

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #